Von Hippel-Lindau (VHL) SyndromeSymptoms, Doctors, Treatments, Advances & More
Learn About Von Hippel-Lindau (VHL) Syndrome
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Rogel Cancer Center
Dr. Else’s primary appointment is with the Division of Metabolism, Endocrinology and Diabetes. He received his MD degree from the University of Hamburg, Germany. He pursued his clinical training at the University of Hamburg (Residency: Internal Medicine) and the University of Michigan (Residency: Internal Medicine, Fellowship: Endocrinology). His main research interests are the genetics of endocrine tumors. Dr. Else’s clinical practice focuses on the care for patients with benign and malignant endocrine tumors, particularly pheochromocytoma, adrenocortical tumors and neuroendocrine tumors as well as accompanying hormone excess syndromes (e.g Cushing syndrome, primary aldosteronism). Dr. Else has a particular interest in taking care of patients with hereditary syndromes that predispose to the development of endocrine tumors (e.g. Multiple Endocrine Neoplasia (MEN) type 1, MEN2A & MEN2B, Hereditary Paraganglioma Syndrome). He attends the Multidisciplinary Endocrine Oncology Clinic, where patients with tumors receive diagnostic procedures and treatment. In addition he is part of the Cancer Genetics Clinic, which evaluates patients for hereditary syndromes and also facilitates regular exams and surveillance for patients at risk for endocrine tumors. Dr. Else is rated as an Elite provider by MediFind in the treatment of Von Hippel-Lindau (VHL) Syndrome. He is also highly rated in 105 other conditions, according to our data. His clinical expertise encompasses Adrenal Cancer, Adrenocortical Carcinoma, Adrenal Gland Adenoma, Neuroendocrine Tumor, and Thyroidectomy. Dr. Else is board certified in Internal Medicine and Endocrinology, Diabetes & Metabolism.
Francesco Montorsi practices practicing medicine in Milan, Italy. Mr. Montorsi is rated as an Elite expert by MediFind in the treatment of Von Hippel-Lindau (VHL) Syndrome. He is also highly rated in 56 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Bladder Cancer, Renal Cell Carcinoma (RCC), Prostatectomy, and Cystectomy.
Kan Gong practices practicing medicine in Beijing, China. Mr. Gong is rated as an Elite expert by MediFind in the treatment of Von Hippel-Lindau (VHL) Syndrome. He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Von Hippel-Lindau (VHL) Syndrome, Hemangioblastoma, Renal Cell Carcinoma (RCC), Nephrectomy, and Thrombectomy.
Summary: This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal stromal tumor (wt GIST), or advanced solid tumors with hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterati...
Summary: Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors: * Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery * Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids * VHL-related tumors are tumors caused by VHL disease. VHL disease is pass...